Tel Aviv Sourasky Medical Center is the first site in the country to conduct the trial for Tourette’s Syndrome. Credit: Gerd Altmann from Pixabay.

SciSparc has obtained final approval from Tel Aviv Sourasky Medical Center in Israel to initiate its Phase IIb trial of SCI-110 for the treatment of Tourette’s Syndrome (TS).

The centre is the first site in the country to conduct the trial.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Tel Aviv Sourasky Medical Center Department of Neurology Movement Disorders Unit head Tanya Gurevich will lead the trial at the centre.

The randomised, double-blind, placebo-controlled, cross-over trial has been designed to assess the efficacy, safety and tolerability of daily oral dose of SCI-110 to treat adult patients with TS.

It will include patients between the age group of 18 and 65 years.

See Also:

During the trail, patients will be randomised into a 1:1 ratio to take either SCI-110 or a placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial’s primary efficacy objective is the assessment of tic severity change by employing Yale Global Tic Severity Scale as a nonstop endpoint at week 12 and week 26 of the double-blind phase in comparison with the baseline.

Its primary safety objective is the review of absolute and relative frequencies of serious adverse events for all the patients as well as separately for the patients receiving SCI-110 and placebo.

SciSparc also plans to undertake the trial in a number of sites, including Yale Child Study Center, Yale School of Medicine, Connecticut.

SciSparc CEO Oz Adler said: “TS is estimated to affect 0.5-1% of the world’s population, however, the very few available treatments have limited efficacy and questionable safety.

“Based on previous results from our Phase IIa trial conducted at Yale University, we believe our proprietary SCI-110 treatment has the potential to help TS patients around the world.”